Navigation Links
Melanoma vaccine strategy shows promise in laboratory experiments

A novel approach to creating a vaccine to treat melanoma has demonstrated promising effectiveness in a new laboratory study led by researchers at The Wistar Institute. About a third of melanoma patients might benefit from such a vaccine. The study appears in the current issue of Cancer Research.

In the study, the scientists used a small protein called a peptide found in approximately 70 percent of melanomas, but not in normal cells, to stimulate immune cells called killer T cells to attack the melanoma cells. Another type of immune cell called a monocyte was used to present the peptide, BRAFV600E, to the killer T cells to trigger their attack on the melanoma cells.

"In our experiments, we saw a strong cancer-killing immune response when killer T cells are stimulated with this peptide," says Dorothee Herlyn, D.V.M., senior author on the study and a professor in the Immunology Program and Molecular and Cellular Oncogenesis Program at Wistar. "The results emphasize the potential of this approach for creating an effective melanoma vaccine, and we hope to move toward human clinical trials as soon as possible."

A substantial proportion of melanoma patients, about 50 percent, have killer T cells able to recognize the BRAFV600E peptide. Combining the prevalence of the peptide among melanoma patients ?about 70 percent ?with the number of patients whose immune cells are able to respond to the peptide suggests that a vaccine based on BRAFV600E could treat approximately a third of all melanoma patients.

Herlyn adds that the specificity of the peptide ?the fact that it is found only in melanoma cells, not normal cells ?suggests that the toxicity of any vaccine based on the peptide would be minimal. Killer T cells sparked into action by the vaccine would target only the cancer cells, sparing healthy cells entirely.

Looking ahead to possible human clinical trials, another member of the scientific team, University of Pennsylvania assistant pro
'"/>

Source:The Wistar Institute


Page: 1 2

Related biology news :

1. NCI Researchers Confirm the Effectiveness of Immunotherapy Approach to Treating Melanoma
2. Research advances quest for HIV-1 vaccine
3. A much-needed shot in the arm for HIV vaccine development
4. Discovery of key proteins shape could lead to improved bacterial pneumonia vaccine
5. Gene vaccine for Alzheimers disease shows promising results
6. Influenza vaccine uses insect cells to speed development
7. Norovirus, AIDS vaccine and Hepatitis Virus
8. HIV vaccine trial breaks ground for future research
9. Live vaccines more effective against horse herpes virus
10. NIAID begins clinical trial of West Nile virus vaccine
11. Designing vaccines by computer
Post Your Comments:
(Date:8/28/2014)... the University of Minnesota have developed an animal research ... for muscle regeneration research as well as studies of ... research is published in the current edition of the ... treatment for FSHD, which is thought by many to ... is an unusual genetic disorder because, unlike most genetic ...
(Date:8/28/2014)... DURHAM, N.C. -- Scientists have identified the developmental on-off ... microbes that produce more than two-thirds of the world,s ... would be to see whether it is possible to ... efficient. , The study, appearing August 28 in ... a small molecule called cyclic-di-GMP and a larger protein ...
(Date:8/28/2014)... to Research Careers) Program has announced the travel ... Medicine,s Conference on Integrative Physiology of Exercise from ... awards are meant to promote the entry of ... into the mainstream of the basic science community ... at the American College of Sports Medicine,s Conference ...
Breaking Biology News(10 mins):UMN researchers find animal model for understudied type of muscular dystrophy 2Small molecule acts as on-off switch for nature's antibiotic factory 2Small molecule acts as on-off switch for nature's antibiotic factory 3
... comprehensive data system that can be used as a ... access to chemical toxicity information. Hao Zhu, ... profiling system" from existing bioassay data from public resources. ... who are seeking information on chemicals of specific environmental ...
... research shows that the Plasmodium vivax ... 2010, may be "rapidly evolving" to overcome the natural resistance ... scientists reported today at the annual meeting of the American ... In large swaths of sub-Saharan Africa, some 95 percent ...
... and Cleveland Clinic Lerner Research Institute have discovered recent ... million cases of malaria annuallychanges that may render tens ... susceptible to infection. Peter A. Zimmerman, professor of ... Reserve School of Medicine, and David Serre, a scientific ...
Cached Biology News:Toxicity database under development at Rutgers-Camden 2New research finds potential risk for millions in Africa believed resistant to vivax malaria 2New research finds potential risk for millions in Africa believed resistant to vivax malaria 3New research finds potential risk for millions in Africa believed resistant to vivax malaria 4Vivax malaria may be evolving around natural defense 2Vivax malaria may be evolving around natural defense 3
(Date:8/28/2014)... 2014 Whitehouse Laboratories is excited to ... with PTI Inspection Systems that will enable ... the art leak testing method development and validation programs ... available. As part of this agreement, Whitehouse Labs has ... Detection Instrument developed and manufactured by PTI. The ...
(Date:8/27/2014)... (PRWEB) August 27, 2014 Green & ... in Series B funding and secured Otter Capital as ... capital will accelerate commercialization of GGI’s Agriplier™ technology, building ... types. , “Since our first meeting, we have ... the biological product space,” said Alan Sobba, President and ...
(Date:8/27/2014)... Livermore, California (PRWEB) August 27, 2014 ... (LLNL), through Lawrence Livermore National Security ... million to develop and deliver a state-of-the-art laser ... Beamlines facility (ELI Beamlines), under construction in the ... design performance, the laser system, called the " ...
(Date:8/27/2014)... Aug. 27, 2014   MSC , a healthcare ... today announced the appointment of Mary Beth Loesch ... 28 years of experience preparing companies for rapid growth ... Executive Vice President of Corporate Development and Healthcare. In ... business , as well as corporate strategy and marketing. ...
Breaking Biology Technology:Whitehouse Labs Renews Partnership with PTI Inspection Systems 2Whitehouse Labs Renews Partnership with PTI Inspection Systems 3Green & Grow Inc. Secures $6M Series B Funding from Otter Capital 2Green & Grow Inc. Secures $6M Series B Funding from Otter Capital 3LLNL Synchs up with ELI Beamlines on Timing System 2LLNL Synchs up with ELI Beamlines on Timing System 3MSC names Mary Beth Loesch President and CEO 2
... Sciences today presented important new results on the ... HIV-1 at the 16th CROI meeting held this ... development of ImQuest,s lead HIV pyrimidinedione inhibitor, IQP-0410. ... exhibiting a dual mechanism of action which includes ...
... 3SBio Inc.,(Nasdaq: SSRX ), a leading ... biopharmaceutical products primarily,in China, today announced that it ... effective February 1, 2009. Since joining 3SBio in ... financial advisor for the company, providing advice,on the ...
... Artemis Health Inc., a,privately-held company dedicated to the ... Richard Rava, Ph.D., has joined Artemis,Health in the ... research and,development. , "Rich,s ... together with his proven track record in commercializing ...
Cached Biology Technology:ImQuest Presents IND-Enabling Safety Pharmacology and Pharmacokinetic Data for the Therapeutic HIV Compound IQP-0410 at Conference on Retroviruses and Opportunistic Infections 23SBio Inc. Appoints Mr. Bo Tan as Chief Financial Officer 2Artemis Health Hires Richard Rava, Ph.D., as Senior Vice President of Research and Development 2Artemis Health Hires Richard Rava, Ph.D., as Senior Vice President of Research and Development 3
... Pierce offers maleimide activated carrier proteins ... conjugates. Imject Maleimide Activated Carrier Proteins ... been preactivated with a heterobifunctional cross-linker ... stable, sulfhydryl-reactive carrier protein. Thus ...
Cell Culture Flask, 25 cm, tissue-culture treated polystyrene...
Cell Culture Flask, nontreated polystyrene...
iNOS/NOS Type II Purified Anti-Mouse, Anti-Rat, Anti-Human clone Polyclonal, Isotype Rabbit Ig, 150 µg Consult technical datasheet for details....
Biology Products: